TD Cowen downgraded Humana from Buy to Hold and set a new price target of $261.00 from $402.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | $247.00 → $308.00 | Underperform → Neutral | BofA Securities |
| 10/11/2024 | Sector Weight | KeyBanc Capital Markets | |
| 10/8/2024 | $308.00 | Mkt Perform → Outperform | Bernstein |
| 10/7/2024 | $402.00 → $261.00 | Buy → Hold | TD Cowen |
| 10/7/2024 | $519.00 → $253.00 | Buy → Hold | Jefferies |
| 10/3/2024 | $392.00 → $274.00 | Overweight → Neutral | Piper Sandler |
| 10/2/2024 | $376.00 → $247.00 | Neutral → Underperform | BofA Securities |
| 10/2/2024 | $400.00 → $250.00 | Outperform → Market Perform | Leerink Partners |
4 - HUMANA INC (0000049071) (Issuer)
Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enterprise talent strategy and people programs for Humana's more than 63,000 employees. She brings a proven track record of transforming HR capabilities and enabling companies to effectively attract, recruit, develop and retain a talented and diverse workforce. O'Hara will report directly to Humana President and CEO Jim Rechtin. "Humana's people strategy is a core capability for our business that supports and empowers our workforce so they can successfully deliver on our mission to make it easier
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
David Dintenfass to lead new centralized function focused on customer experience, sales and marketing Leading health insurer and health care services company Humana Inc. (NYSE:HUM) announced today that it has named David Dintenfass as President of Enterprise Growth. In this new role, Dintenfass will have responsibility for leading the company's growth plan with a primary focus on customer acquisition, retention, and experience. The creation of this position, and its emphasis on the customer and digital experience, will help Humana deliver on its long-term strategy and maximize long-term growth within the Medicare Advantage market. By 2030, one in five Americans is projected to be 65 years
Builds On Ongoing Collaboration With Google Health To Develop Population Health Solutions And Address Healthcare Challenges
TD Cowen analyst Gary Taylor maintains Humana (NYSE:HUM) with a Buy and raises the price target from $396 to $407.
Cantor Fitzgerald analyst Sarah James reiterates Humana (NYSE:HUM) with a Neutral and maintains $360 price target.
4 - HUMANA INC (0000049071) (Issuer)
3 - HUMANA INC (0000049071) (Issuer)
4 - HUMANA INC (0000049071) (Issuer)
Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enterprise talent strategy and people programs for Humana's more than 63,000 employees. She brings a proven track record of transforming HR capabilities and enabling companies to effectively attract, recruit, develop and retain a talented and diverse workforce. O'Hara will report directly to Humana President and CEO Jim Rechtin. "Humana's people strategy is a core capability for our business that supports and empowers our workforce so they can successfully deliver on our mission to make it easier
Humana Inc. (NYSE:HUM) has been recognized by both Military Times and Military Friendly® as a top employer for veterans and military families. Military Times, a leading source for independent news and information for service members and their families, ranked Humana #14 in its Healthcare category on its 2024 Best for Vets: Employers list. Now in its 15th year, Military Times Best for Vets rankings are based on a voluntary survey covering policies and practices that make companies attractive to the military community. Recruitment and employment practices, as well as retention and support programs, are given the most weight and importance in scoring and final rankings. Military Friendly®,
Partnership Focuses on Improving Prior Authorization Process, Helping Drive Better Patient Outcomes Humana Inc. (NYSE:HUM) and Evolent Health, Inc. (NYSE:EVH) announced they have expanded their strategic medical oncology partnership to modernize and streamline prior authorization processes to include radiation and surgical oncology services. By connecting all primary approaches to treating cancer, this collaboration will help expedite approval of prior authorization requests, improve patient access to care, and ensure timely access to critical treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107578119/en/ "This part
SC 13G/A - HUMANA INC (0000049071) (Subject)
SC 13G/A - HUMANA INC (0000049071) (Subject)
SC 13G/A - HUMANA INC (0000049071) (Subject)
BofA Securities upgraded Humana from Underperform to Neutral and set a new price target of $308.00 from $247.00 previously
KeyBanc Capital Markets initiated coverage of Humana with a rating of Sector Weight
Bernstein upgraded Humana from Mkt Perform to Outperform and set a new price target of $308.00
10-Q - HUMANA INC (0000049071) (Filer)
8-K - HUMANA INC (0000049071) (Filer)
8-K - HUMANA INC (0000049071) (Filer)
Reports 3Q24 earnings per share (EPS) of $3.98 on a GAAP basis, Adjusted EPS of $4.16; reports YTD 2024 EPS of $15.72 on a GAAP basis, $18.35 on an Adjusted basis Updates FY 2024 EPS guidance to 'at least $12.89' on a GAAP basis, 'at least $16.00' on an Adjusted basis; affirms FY 2024 Insurance segment benefit ratio of approximately 90 percent Raises 2024 individual Medicare Advantage annual membership growth by 40,000 to now anticipate annual growth of approximately 265,000, or approximately 5 percent Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 9:00 a.m. ET question and answer session to discuss its financial results for
Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on January 31, 2025 to stockholders of record as of the close of business on December 31, 2024. About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, milita
Humana Inc. (NYSE:HUM) will release its financial results for the third quarter 2024 (3Q24), as well as prepared management remarks (in PDF format), on Wednesday, October 30, 2024, at 6:30 a.m. Eastern time. The company will host a live question and answer session at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2024. To participate via telephone, please register in advance using this link, https://register.vevent.com/register/BI66effa11b1e4494d907df29b87d7d237. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique regi